Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Lehman Notes Lawsuit Filed Against UBS Over Deceptive Sales August 26, 2010 Staff Writers Add Your Comments A financial fraud lawsuit has been filed against UBS by an Indiana couple who claim the brokerage firm sold them high risk Lehman structured notes while claiming they were safe and protected. The Lehman Brothers notes lawsuit was filed earlier this month before the Financial Industry Regulatory Authority (FINRA), and is the latest in a string of claims against UBS over problems with the structured notes. In addition to selling the couple the Lehman notes, the lawsuit claims that UBS also sold them its own structured notes, which the investors allege was a violation in spirit of an industry rule that disallows a broker to borrow from its customers. The UBS lawsuit seeks to recover the entire investment by the couple, which has not been disclosed, as well as attorney’s fees, costs, and punitive damages in an amount of triple what the couple lost. Do You Know about… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Do You Know About… hair dye cancer lawsuits For Salon Professionals Hair dye lawsuits are being pursued for salon professionals who were routinely exposed to hair dye chemicals and diagnosed with bladder cancer or breast cancer. See if you qualify for a hair dye cancer lawsuit settlement. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Lehman Brothers structured notes were a hybrid financial instrument, constructed from a combination of stocks, bonds, currencies, commodities and derivatives, which were promoted by some brokers as low-risk investments, even as Lehman Brothers faced substantial financial troubles. Although investors were told that the notes carried a guaranteed principal protection, that guarantee became worthless when Lehman filed for bankruptcy protection on September 15, 2008. FINRA is a non-governmental regulatory body that oversees more than 5,000 brokerage firms throughout the United States. Investors are able to resolve disputes against brokerage firms through FINRA for claims involving breach of fiduciary duty, negligence, misrepresentation, breach of contract, unauthorized trading and other claims that investments were improperly handled. A UBS class action lawsuit over Lehman structured notes was filed in 2008 in the U.S. District Court for the Southern District of New York, on behalf of all investors who were sold the investment by the brokerage firm. The complaint alleges that UBS brokers made false and misleading statements about Lehman Brothers Principal Protection Notes that omitted material facts about the risk associated with investing. However, according to financial fraud lawyers investigating Lehman Brothers claims on behalf of investors, most individuals are in a better position to recover their losses through a FINRA arbitration claim. Observers say that more UBS Lehman notes lawsuits could be coming from states and the Securities Exchange Commission could file criminal charges as financial law enforcement investigators look deeper into the brokerage firm’s practices in promoting and selling the notes. Tags: Financial Fraud, FINRA, FINRA Arbitration, Indiana, Lehman Brothers, UBS Image Credit: | More Lawsuit Stories Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis May 1, 2025 Nitrous Oxide Addiction Lawsuit Claims Manufacturer Concealed Galaxy Gas Side Effects May 1, 2025 Roundup Exposure May Increase Infertility, Endometriosis Risks: Study May 1, 2025 1 Comments Michael August 26, 2010 What UBS did in the US, Credit Suisse practiced in Switzerland. It is estimated that Credit Suisse sold principal-protected Lehman notes worth about 700 million Swiss francs in Switzerland alone. The clients were mostly small investors with little or no experience in capital markets. Just as UBS, Credit Suisse failed to inform the customers about the true nature of these products. Just look at a factsheet of a Lehman note sold be Credit Suisse. In the section entitled “risks” you will find neither “Lehman” nor “creditworthiness of the issuer” nor anything similar. Instead – throughout the entiire document – you will find five times the promise “principal protected” – but not a single time in conjunction with Lehman, at least not explicitly. What in my view proves the accusation of deception is the fact that in a sales brochure issued by Credit Suisse, these opportunity notes carry the risk label “low” (see brochure entitled “Anlegen und Vorsorgen”), whereas in the disclaimer of such a note, there is talk of “high” risks. It is obvious that one was text written by marketing people and the other by legal staff and that Credit Suisse failed to reconcile the two. The version the relationship managers stuck to is of course the first one, as you can see from an e-mail sent by my relationship manager. He recommends the Lehman note as an alternative to a fixed deposit and claims that it is FULLY principal-protected (capital letters by Credit Suisse). No mention of Lehman, issuer or issuer risk. In the mean-time, Credit Suisse was forced to buy back about 150 Mio. Swiss francs worth of these notes – not by our financial market supervisory authority, which is totally useless, but by public pressure. This is of course barely more than 20% of what Credit Suisse had sold. At the end of February 2010, Credit Suisse was still advertising structured products on its website with the slogan “Protect your portfolio against unexpected risks with structured derivatives.” The Opportunity Note that was then presented featured repeated emphasis on one-hundred-percent capital protection without a single mention of issuer risk. The Opportunity Note was then awarded a lovely “low” risk value. However, one look at the fine-print disclaimer of such an Opportunity Note would immediately reveal the phrase “These investment products are complex structured derivatives and involve a high degree of risk.” Depending on whether the print is large or small, the risk ranges from low to high; sometimes the Opportunity Note protects against unexpected risks, sometimes it involves a high degree of risk in itself. Even the brochure “Special Risks in Securities Trading” by the Swiss Bankers Association – a brochure which is sent to the customers when they open up a depot, i.e. years before they may actually buy a principal-protected product or, depending on the circumstances, also afterwards – even this brochure fails to explain the relationship between issuer risk and principal protection. As a matter of fact, this brochure even cements what principal protection means to the layman anyway: “What is the maximum possible loss? The maximum possible loss for the buyer of a structured product with capital protection is the difference between the purchase price and the amount of the capital protection.” (Special Risks in Securities Trading, Swiss Bankers Association, Edition 2001, in use until 2008, p. 14) I hope that justice will one day prevail in both the US and Switzerland. Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermEmailThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (Posted: today) A Wisconsin woman has filed a Depo-Provera brain tumor lawsuit, alleging that she continued using the birth control injection for years after her diagnosis due to the manufacturers’ failure to provide adequate warnings about the potential risk of developing a meningioma. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025)Depo-Provera Use for Endometriosis Caused Stroke-Like Symptoms, Golf Ball-Sized Brain Tumor: Lawsuit (04/15/2025)Depo-Provera Lawsuit Case Management Conferences Scheduled Throughout 2025 (04/08/2025) Sports Gambling Addiction Crisis Fueled By Sportsbook App Lobbying Efforts: Report (Posted: yesterday) Following the rapid expansion of legalized sports betting across the U.S., a new watchdog report reveals how the gambling industry lobbied against consumer protections to prevent sports betting addictions, while wagers reached $148 billion annually. MORE ABOUT: SPORTS BETTING ADDICTION LAWSUITDraftKings Class Action Lawsuit Alleges Enormous Revenue Generated by Misleading Gamblers (04/23/2025)DraftKings and FanDuel Lawsuit Alleges Sportsbooks Engage in Deceptive Practices To Exploit Gambling Addiction (04/09/2025)Gambling Addiction Lawsuit Filed Against Sports Betting Platform DraftKings (02/20/2025) Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (Posted: yesterday) A group of 11 lawsuits over complications associated with Bard PowerPort and other implantable port catheters will be prepared for a series of early bellwether trials in the federal MDL. MORE ABOUT: BARD POWERPORT LAWSUITBard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025)Bard PowerPort Bellwether Trial Selections To Be Made in Late April 2025 (03/26/2025)Smiths Medical Port Catheter Recall Issued Over Manufacturing Error (03/20/2025)
Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis May 1, 2025
Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (Posted: today) A Wisconsin woman has filed a Depo-Provera brain tumor lawsuit, alleging that she continued using the birth control injection for years after her diagnosis due to the manufacturers’ failure to provide adequate warnings about the potential risk of developing a meningioma. MORE ABOUT: DEPO-PROVERA LAWSUITDepo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025)Depo-Provera Use for Endometriosis Caused Stroke-Like Symptoms, Golf Ball-Sized Brain Tumor: Lawsuit (04/15/2025)Depo-Provera Lawsuit Case Management Conferences Scheduled Throughout 2025 (04/08/2025)
Sports Gambling Addiction Crisis Fueled By Sportsbook App Lobbying Efforts: Report (Posted: yesterday) Following the rapid expansion of legalized sports betting across the U.S., a new watchdog report reveals how the gambling industry lobbied against consumer protections to prevent sports betting addictions, while wagers reached $148 billion annually. MORE ABOUT: SPORTS BETTING ADDICTION LAWSUITDraftKings Class Action Lawsuit Alleges Enormous Revenue Generated by Misleading Gamblers (04/23/2025)DraftKings and FanDuel Lawsuit Alleges Sportsbooks Engage in Deceptive Practices To Exploit Gambling Addiction (04/09/2025)Gambling Addiction Lawsuit Filed Against Sports Betting Platform DraftKings (02/20/2025)
Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (Posted: yesterday) A group of 11 lawsuits over complications associated with Bard PowerPort and other implantable port catheters will be prepared for a series of early bellwether trials in the federal MDL. MORE ABOUT: BARD POWERPORT LAWSUITBard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025)Bard PowerPort Bellwether Trial Selections To Be Made in Late April 2025 (03/26/2025)Smiths Medical Port Catheter Recall Issued Over Manufacturing Error (03/20/2025)